Search

Displaying results 2621 - 2630 of 5900 in total
  1. Drug

    Pipotiazine

    go.drugbank.com/drugs/DB01621
    ApprovedInvestigationalWithdrawn

    Pipotiazine has actions similar to those of other phenothiazines. … Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics.

  2. Drug

    Carmustine

    go.drugbank.com/drugs/DB00262
    ApprovedInvestigational

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985).

  3. Drug

    Tildrakizumab

    go.drugbank.com/drugs/DB14004
    ApprovedInvestigational

    The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

  4. Drug

    Mepolizumab

    go.drugbank.com/drugs/DB06612
    ApprovedInvestigational

    This indication was subsequently expanded to cover EGPA on December 12, 2017, and HES on September 25, 2020.[L16518] … Activated eosinophils further stimulate an inflammatory response and also induce tissue lesions and promote fibrosis, all of which contribute to the multifactorial symptomatology of hypereosinophilic diseases

  5. Drug

    Vaborbactam

    go.drugbank.com/drugs/DB12107
    ApprovedInvestigational

    Vaborbactam is added to the therapy to reduce the extent meropenem degradation by inhibiting the serine beta-lactamases expressed by the microorganism of target. … [Label] The treatment aims to resolve infection-related symptoms of cUTI and achieve negative urine culture, when the infections are proven or strongly suspected to be caused by susceptible bacteria.

  6. Drug

    Acemetacin

    go.drugbank.com/drugs/DB13783
    ApprovedInvestigational

    Merck and Company in Germany as an attempt to provide a safer drug but other than the amelioration on the gastrointestinal effects, the metabolism of acetamicin led to the formation of indomethacin and … [A31352] In clinical trials, acemetacin exhibits a better gastric tolerability compared to its active metabolite indometacin.[T50] It was developed by E.

  7. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    12 years and older to be approved by the FDA. … [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who

  8. Drug

    Anthoxanthum odoratum pollen

    go.drugbank.com/drugs/DB10404
    Approved

    Anthoxanthum odoratum pollen is the pollen of the Anthoxanthum odoratum plant. Anthoxanthum odoratum pollen is mainly used in allergenic testing.

    Mixtures: T-O-S Standardized Grass Pollen Mix, T-O-S Standardized Grass Pollen Mix
  9. Drug

    Sevelamer

    go.drugbank.com/drugs/DB00658
    ApprovedInvestigational

    Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.

    Products: <html>RENALAMER CO<sub>3</sub> 800 MG FILM TABLET, 180 ADET</html>, SEVELAMER DOC GENERICI
  10. Drug

    Indium In-111 oxyquinoline

    go.drugbank.com/drugs/DB09473
    Approved

    Once inside, Indium detaches from the oxyquinoline complexes and becomes attached to cytoplasmic components. … Following intravenous administration, the lipid-soluble complex is able to penetrate platelet cell membranes.